{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:35Z","timestamp":1788415955132,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>With advances in targeted early breast cancer (eBC) treatment, research is needed to understand the factors influencing biomarker testing and respective treatment selection among physicians in routine clinical practice. The purpose of this study was to evaluate factors influencing oncologist decisions for germline BReast Cancer gene (BRCA) mutation (gBRCAm) testing and adjuvant therapy in human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>US oncologists completed an online survey from April to July 2024, which included preference exercises to evaluate the relative importance of select factors for gBRCA testing and adjuvant treatment selection in gBRCAm HER2- eBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 150 surveyed oncologists, age was over twice as influential as tumor size and lymph node involvement in gBRCA testing decisions for hormone receptor-positive (HR+)\/HER2- eBC. Nearly one-quarter reported that gBRCA test results did not impact their treatment decisions. Olaparib-based regimens were the preferred adjuvant treatment for gBRCAm HER2- eBC, over Cyclin-Dependent Kinases 4 and 6 inhibitors alone for HR+\/HER2- eBC, immunotherapy or capecitabine alone for triple-negative eBC, and no treatment. Efficacy was the most important treatment attribute. Oncologists reported that patient unwillingness to undergo gBRCA testing or receive adjuvant olaparib due to cost, treatment duration, or other reasons were barriers to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite guideline recommendations, age drives oncologists\u2019 gBRCA testing decisions. To support the preference for olaparib-based adjuvant treatment in gBRCAm HER2- eBC, increased physician awareness of guidelines and the rationale for gBRCAm testing is needed to improve identification of eligible patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1854965","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:55Z","timestamp":1788412495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing oncologists\u2019 decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Qixin","family":"Li","sequence":"first","affiliation":[{"name":"Oncology Outcomes Research, AstraZeneca","place":["Gaithersburg, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Janelle","family":"Cambron-Mellott","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Research, AstraZeneca","place":["Gaithersburg, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kashine-Tack","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Hayes","sequence":"additional","affiliation":[{"name":"US Medical Affairs Oncology, AstraZeneca","place":["Gaithersburg, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Emily","family":"Mishkin","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc.","place":["Rahway, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gordon","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Will","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Howell","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Noval","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[{"name":"Research Services, Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","unstructured":"U.S. Cancer Statistics Female Breast Cancer Stat Bite\n          \n          \n          U.S. Department of Health and Human Services\n          \n          2024"},{"key":"B2","unstructured":"Cancer Stat Facts: Female Breast Cancer Subtypes"},{"key":"B3","unstructured":"\u00a9 National Comprehensive Cancer Network, Inc.\n          \n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B5","unstructured":"(NCCN Guidelines\u00ae) for Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate V.2.2025. \u00a9 National Comprehensive Cancer Network, Inc.\n          \n          \n          \n          2025"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/medicina56100514","article-title":"Germline BRCA mutation and clinical outcomes in breast cancer patients focusing on survival and failure patterns: a long-term follow-up study of Koreans","volume":"56","author":"Kim","year":"2020","journal-title":"Med Kaunas Lith"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O\u2019Shaughnessy","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3014","article-title":"A multigene assay determines risk of recurrence in patients with triple-negative breast cancer","volume":"79","author":"Stewart","year":"2019","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer","volume":"18","author":"Sheffield","year":"2022","journal-title":"Future Oncol"},{"key":"B16","unstructured":"FDA Approves Abemaciclib With Endocrine Therapy for Early Breast Cancer\n          \n          \n          \n          2021"},{"key":"B17","unstructured":"FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer\n          \n          \n          \n          2024"},{"key":"B18","unstructured":"FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer\n          \n          \n          \n          2021"},{"key":"B19","unstructured":"FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer\n          \n          \n          \n          2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad123","article-title":"Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: evidence and controversies","volume":"28","author":"Morganti","year":"2023","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing","volume":"131","author":"Arun","year":"2024","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1730548","DOI":"10.3389\/fonc.2026.1730548","article-title":"BRCA genetic testing and treatment patterns for patients with HER2-negative early-stage breast cancer in the US community setting","volume":"16","author":"Mishkin","year":"2026","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2196\/32365","article-title":"Understanding uptake of digital health products: methodology tutorial for a discrete choice experiment using the Bayesian efficient design","volume":"23","author":"Szinay","year":"2021","journal-title":"J Med Internet Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Johnson","year":"2013","journal-title":"Value Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000001463","article-title":"A choice-based conjoint analysis of the psychiatrist decision-making process used in determining when to discharge adults with major depressive disorder hospitalized for active suicidal ideation with intent","volume":"210","author":"Voelker","year":"2022","journal-title":"J Nerv Ment Dis"},{"key":"B28","unstructured":"Situational Choice Experiments for Marketing Research: How to Design, Analyze and Report Them\n          \n          \n            \n              Chrzan\n              K\n            \n          \n          \n          2022"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1152123","article-title":"Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study","volume":"13","author":"Di Lisa","year":"2023","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S1257","DOI":"10.1016\/j.annonc.2023.10.008","article-title":"LBA18 pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"B38","volume-title":"LYNPARZA\u00ae (olaparib)","year":"2023"},{"key":"B39","volume-title":"Verzenio (abemaciclib)","year":"2024"},{"key":"B40","volume-title":"XELODA\u00ae (capecitabine)","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000530584","article-title":"St. Gallen\/Vienna 2023: Optimization of treatment for patients with primary breast cancer - a brief summary of the consensus discussion","volume":"18","author":"Balic","year":"2023","journal-title":"Breast Care Basel Switz"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0749-3797(00)00258-0","article-title":"Physician response to surveys. A review of the literature","volume":"20","author":"Kellerman","year":"2001","journal-title":"Am J Prev Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3758\/bf03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"B45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B47","unstructured":"Assessing the Status of BRCA Testing and Challenges Faced by Patients and Cancer Care Teams: BRCA Testing Reassessment\n          \n          \n          \n          2024"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"crossref","unstructured":"Abstract GS01-05: Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study\n          \n          \n            \n              Rugo\n              HS\n            \n            \n              Robson\n              ME\n            \n            \n              Dalenc\n              F\n            \n            \n              Ruiz\n              EY\n            \n            \n              Im\n              Y-H\n            \n            \n              Kulyk\n              S\n            \n          \n          \n          2023","DOI":"10.1158\/1538-7445.SABCS23-GS01-05"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","article-title":"Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer","volume":"31","author":"Garber","year":"2025","journal-title":"Clinical Cancer Research"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40271-025-00783-1","article-title":"Factors influencing patient preferences for BRCA testing and adjuvant therapy in HER2-negative early breast cancer in the United States: Best\u2013worst scaling and discrete choice experiment","volume":"19","author":"Mishkin","year":"2026","journal-title":"Patient"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:57Z","timestamp":1788412497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":53,"alternative-id":["10.3389\/fonc.2026.1854965"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1854965","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1854965"}}